Machina Capital S.A.S. Incyte Corp Transaction History

Machina Capital S.A.S.

$238 Million
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$51.18 - $63.75 $338,862 - $422,088	6,621 New	6,621 $401,000
Q4 2023 Feb 06, 2024	SELL	$52.16 - $64.19 $248,594 - $305,929	-4,766 Reduced 38.19%	7,715 $484,000
Q3 2023 Nov 02, 2023	BUY	$57.77 - $65.93 $447,601 - $510,825	7,748 Added 163.7%	12,481 $721,000
Q2 2023 Aug 08, 2023	SELL	$60.95 - $75.51 $357,654 - $443,092	-5,868 Reduced 55.35%	4,733 $294,000
Q1 2023 Apr 24, 2023	BUY	$70.23 - $86.01 $452,421 - $554,076	6,442 Added 154.89%	10,601 $766,000
Q4 2022 Feb 08, 2023	SELL	$67.18 - $84.11 $133,822 - $167,547	-1,992 Reduced 32.38%	4,159 $334,000
Q3 2022 Nov 10, 2022	BUY	$66.18 - $82.86 $133,749 - $167,460	2,021 Added 48.93%	6,151 $410,000
Q2 2022 Aug 08, 2022	BUY	$66.18 - $83.18 $87,026 - $109,381	1,315 Added 46.71%	4,130 $314,000
Q1 2022 Apr 27, 2022	BUY	$66.02 - $79.71 $185,846 - $224,383	2,815 New	2,815 $224,000
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $393,341 - $481,266	-5,728 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $457,495 - $501,371	5,728 New	5,728 $482,000
Q1 2020 May 05, 2020	SELL	$63.18 - $85.97 $249,245 - $339,151	-3,945 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$73.04 - $95.72 $556,418 - $729,194	-7,618 Reduced 65.88%	3,945 $344,000
Q3 2019 Nov 12, 2019	BUY	$72.82 - $86.52 $29,200 - $34,694	401 Added 3.59%	11,563 $858,000
Q2 2019 Jul 19, 2019	SELL	$73.52 - $88.7 $32,201 - $38,850	-438 Reduced 3.78%	11,162 $948,000
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $689,053 - $955,850	10,841 Added 1428.33%	11,600 $998,000
Q4 2018 Mar 25, 2019	BUY	$58.5 - $69.94 $44,401 - $53,084	759 New	759 $48,000

Others Institutions Holding INCY

# of Institutions

642

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Machina Capital S.A.S., based on Form 13F filings with the SEC.

News

Stay updated on Machina Capital S.A.S. with notifications on news.

Account